2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

Jasvinder A. Singh, Kenneth G. Saag, S. Louis Bridges, Elie A. Akl, Raveendhara R. Bannuru, Matthew C. Sullivan, Elizaveta Vaysbrot, Christine McNaughton, Mikala Osani, Robert H. Shmerling, Jeffrey R. Curtis, Daniel E. Furst, Deborah Parks, Arthur Kavanaugh, James Robert O'Dell, Charles King, Amye Leong, Eric L. Matteson, John T. Schousboe, Barbara DrevlowSeth Ginsberg, James Grober, E. William St.clair, Elizabeth Tindall, Amy S. Miller, Timothy McAlindon

Research output: Contribution to journalArticle

1063 Citations (Scopus)

Abstract

Objective To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional. Conclusion This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.

Original languageEnglish (US)
Pages (from-to)1-26
Number of pages26
JournalArthritis and Rheumatology
Volume68
Issue number1
DOIs
StatePublished - Jan 1 2016

Fingerprint

Antirheumatic Agents
Biological Factors
Rheumatoid Arthritis
Guidelines
Patient Preference
Therapeutics
Group Processes
Glucocorticoids
Hepatitis
Uncertainty
Comorbidity
Consensus
Decision Making
Tuberculosis
Vaccines
Heart Failure
Physicians
Infection
Neoplasms

ASJC Scopus subject areas

  • Immunology and Allergy
  • Rheumatology
  • Immunology

Cite this

Singh, J. A., Saag, K. G., Bridges, S. L., Akl, E. A., Bannuru, R. R., Sullivan, M. C., ... McAlindon, T. (2016). 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis and Rheumatology, 68(1), 1-26. https://doi.org/10.1002/art.39480

2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. / Singh, Jasvinder A.; Saag, Kenneth G.; Bridges, S. Louis; Akl, Elie A.; Bannuru, Raveendhara R.; Sullivan, Matthew C.; Vaysbrot, Elizaveta; McNaughton, Christine; Osani, Mikala; Shmerling, Robert H.; Curtis, Jeffrey R.; Furst, Daniel E.; Parks, Deborah; Kavanaugh, Arthur; O'Dell, James Robert; King, Charles; Leong, Amye; Matteson, Eric L.; Schousboe, John T.; Drevlow, Barbara; Ginsberg, Seth; Grober, James; St.clair, E. William; Tindall, Elizabeth; Miller, Amy S.; McAlindon, Timothy.

In: Arthritis and Rheumatology, Vol. 68, No. 1, 01.01.2016, p. 1-26.

Research output: Contribution to journalArticle

Singh, JA, Saag, KG, Bridges, SL, Akl, EA, Bannuru, RR, Sullivan, MC, Vaysbrot, E, McNaughton, C, Osani, M, Shmerling, RH, Curtis, JR, Furst, DE, Parks, D, Kavanaugh, A, O'Dell, JR, King, C, Leong, A, Matteson, EL, Schousboe, JT, Drevlow, B, Ginsberg, S, Grober, J, St.clair, EW, Tindall, E, Miller, AS & McAlindon, T 2016, '2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis', Arthritis and Rheumatology, vol. 68, no. 1, pp. 1-26. https://doi.org/10.1002/art.39480
Singh, Jasvinder A. ; Saag, Kenneth G. ; Bridges, S. Louis ; Akl, Elie A. ; Bannuru, Raveendhara R. ; Sullivan, Matthew C. ; Vaysbrot, Elizaveta ; McNaughton, Christine ; Osani, Mikala ; Shmerling, Robert H. ; Curtis, Jeffrey R. ; Furst, Daniel E. ; Parks, Deborah ; Kavanaugh, Arthur ; O'Dell, James Robert ; King, Charles ; Leong, Amye ; Matteson, Eric L. ; Schousboe, John T. ; Drevlow, Barbara ; Ginsberg, Seth ; Grober, James ; St.clair, E. William ; Tindall, Elizabeth ; Miller, Amy S. ; McAlindon, Timothy. / 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. In: Arthritis and Rheumatology. 2016 ; Vol. 68, No. 1. pp. 1-26.
@article{40003dfa592f4f32b25588ca3d1d6f9f,
title = "2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis",
abstract = "Objective To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23{\%} are strong and 77{\%} are conditional. Conclusion This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.",
author = "Singh, {Jasvinder A.} and Saag, {Kenneth G.} and Bridges, {S. Louis} and Akl, {Elie A.} and Bannuru, {Raveendhara R.} and Sullivan, {Matthew C.} and Elizaveta Vaysbrot and Christine McNaughton and Mikala Osani and Shmerling, {Robert H.} and Curtis, {Jeffrey R.} and Furst, {Daniel E.} and Deborah Parks and Arthur Kavanaugh and O'Dell, {James Robert} and Charles King and Amye Leong and Matteson, {Eric L.} and Schousboe, {John T.} and Barbara Drevlow and Seth Ginsberg and James Grober and St.clair, {E. William} and Elizabeth Tindall and Miller, {Amy S.} and Timothy McAlindon",
year = "2016",
month = "1",
day = "1",
doi = "10.1002/art.39480",
language = "English (US)",
volume = "68",
pages = "1--26",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "1",

}

TY - JOUR

T1 - 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis

AU - Singh, Jasvinder A.

AU - Saag, Kenneth G.

AU - Bridges, S. Louis

AU - Akl, Elie A.

AU - Bannuru, Raveendhara R.

AU - Sullivan, Matthew C.

AU - Vaysbrot, Elizaveta

AU - McNaughton, Christine

AU - Osani, Mikala

AU - Shmerling, Robert H.

AU - Curtis, Jeffrey R.

AU - Furst, Daniel E.

AU - Parks, Deborah

AU - Kavanaugh, Arthur

AU - O'Dell, James Robert

AU - King, Charles

AU - Leong, Amye

AU - Matteson, Eric L.

AU - Schousboe, John T.

AU - Drevlow, Barbara

AU - Ginsberg, Seth

AU - Grober, James

AU - St.clair, E. William

AU - Tindall, Elizabeth

AU - Miller, Amy S.

AU - McAlindon, Timothy

PY - 2016/1/1

Y1 - 2016/1/1

N2 - Objective To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional. Conclusion This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.

AB - Objective To develop a new evidence-based, pharmacologic treatment guideline for rheumatoid arthritis (RA). Methods We conducted systematic reviews to synthesize the evidence for the benefits and harms of various treatment options. We used the Grading of Recommendations Assessment, Development and Evaluation (GRADE) methodology to rate the quality of evidence. We employed a group consensus process to grade the strength of recommendations (either strong or conditional). A strong recommendation indicates that clinicians are certain that the benefits of an intervention far outweigh the harms (or vice versa). A conditional recommendation denotes uncertainty over the balance of benefits and harms and/or more significant variability in patient values and preferences. Results The guideline covers the use of traditional disease-modifying antirheumatic drugs (DMARDs), biologic agents, tofacitinib, and glucocorticoids in early (<6 months) and established (≥6 months) RA. In addition, it provides recommendations on using a treat-to-target approach, tapering and discontinuing medications, and the use of biologic agents and DMARDs in patients with hepatitis, congestive heart failure, malignancy, and serious infections. The guideline addresses the use of vaccines in patients starting/receiving DMARDs or biologic agents, screening for tuberculosis in patients starting/receiving biologic agents or tofacitinib, and laboratory monitoring for traditional DMARDs. The guideline includes 74 recommendations: 23% are strong and 77% are conditional. Conclusion This RA guideline should serve as a tool for clinicians and patients (our two target audiences) for pharmacologic treatment decisions in commonly encountered clinical situations. These recommendations are not prescriptive, and the treatment decisions should be made by physicians and patients through a shared decision-making process taking into account patients' values, preferences, and comorbidities. These recommendations should not be used to limit or deny access to therapies.

UR - http://www.scopus.com/inward/record.url?scp=84956767541&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84956767541&partnerID=8YFLogxK

U2 - 10.1002/art.39480

DO - 10.1002/art.39480

M3 - Article

C2 - 26545825

AN - SCOPUS:84956767541

VL - 68

SP - 1

EP - 26

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 1

ER -